```html

Eye Pterygium – A Complete Medical Guide

Overview

What is a pterygium? A pterygium (pronounced ter‑mi‑gee‑um) is a benign, wedge‑shaped growth of fibrovascular tissue that originates from the conjunctiva (the clear membrane covering the white of the eye) and extends onto the cornea. Most often it appears on the nasal side of the eye, but in rare cases it can affect the temporal side.

Who does it affect? The condition is most common in adults aged 30–60 years, especially those who spend a lot of time outdoors. It is slightly more prevalent in men, likely because of occupational sun exposure.

Prevalence – Population‑based studies estimate a prevalence ranging from 3% to 30% worldwide, with higher rates in sunny, coastal regions (e.g., 30‑40% among outdoor workers in the Mediterranean and South‑East Asia) <sup>[1][2]</sup>. In the United States, about 5% of adults have a clinically significant pterygium, and the rate climbs to >10% in people of Hispanic or Asian descent <sup>[3]</sup>.

Symptoms

Many pterygia are asymptomatic at first, but as they enlarge they can cause a variety of ocular complaints. Below is a comprehensive list:

• Redness (conjunctival hyperemia): The affected eye may appear more blood‑shot than the fellow eye.
• Foreign‑body sensation: Patients often describe a gritty feeling, as if sand is in the eye.
• Itching or mild burning: Irritation is common, especially after wind exposure.
• Tearing (epiphora): Excessive tearing can result from ocular surface irritation.
• Dryness: Paradoxically, the eye may feel dry because the abnormal tissue disrupts the tear film.
• Blurred or reduced vision: When the pterygium encroaches on the visual axis, it can cause astigmatism or direct blockage.
• Glare and photophobia: Light sensitivity increases when the lesion becomes large.
• Cosmetic concerns: The growth is usually whitish‑gray with a pinkish blood supply, which some patients find cosmetically unsettling.
• Recurrence after surgery: A returned pterygium can cause the same set of symptoms.

Causes and Risk Factors

Primary cause – UV light exposure

Ultraviolet‑A (UVA) and UVB radiation induce DNA damage and stimulate fibroblast proliferation in the conjunctiva. The “UV‑induced elastotic degeneration” hypothesis explains why the nasal side, which receives the most reflected sunlight from the cheekbone, is most frequently involved.

Other contributing factors

• Chronic ocular irritation: Wind, dust, sand, and smoke act as mechanical irritants that promote fibrovascular growth.
• Genetic predisposition: Some family clusters suggest a heritable component, although specific genes are not yet identified.
• Dry eye syndrome: An unstable tear film can increase conjunctival inflammation.
• Age: Cumulative UV exposure over decades raises risk.
• Geography: Living closer to the equator or at high altitude increases UV intensity.

High‑risk populations

• Outdoor workers – farmers, fishermen, construction laborers, lifeguards.
• People with light‑colored eyes (blue, gray) who allow more UV to penetrate.
• Individuals with a history of pterygium in the other eye.
• Patients with chronic allergic conjunctivitis.

Diagnosis

Diagnosis is primarily clinical, performed by an eye‑care professional (optometrist or ophthalmologist).

History and symptom review

The clinician asks about occupational sun exposure, duration of symptoms, previous eye surgeries, and any visual changes.

Slit‑lamp examination

A high‑magnification microscope equipped with a bright light (slit‑lamp) lets the doctor view the size, vascularity, and progression of the lesion. The exam also assesses for corneal involvement, surface irregularities, and signs of inflammation.

Ancillary tests (when needed)

• Corneal topography: Maps corneal curvature to detect induced astigmatism.
• Pachymetry: Measures corneal thickness if surgery is being considered.
• Anterior segment OCT (optical coherence tomography): Provides cross‑sectional images of the lesion depth.
• Photography: Baseline and follow‑up photos help track growth over time.

Treatment Options

Management depends on severity, symptoms, and impact on vision.

Conservative (non‑surgical) measures

• Lubricating eye drops: Preservative‑free artificial tears reduce dryness and irritation.
• Topical anti‑inflammatory drops: Mild steroid (e.g., loteprednol) or NSAID drops can decrease redness for short periods (<10 days) under supervision.
• UV‑blocking sunglasses: Wrap‑around glasses with 100% UVA/UVB protection are essential.
• Protective hats: Wide‑brimmed hats reduce direct UV exposure.
• Environmental control: Use of humidifiers and avoidance of wind‑blown dust.

When surgery is indicated

Indications include: progression onto the visual axis, significant cosmetic concern, induced astigmatism (>1.00 D), or persistent inflammation despite medical therapy.

Surgical techniques

• Excisional surgery with conjunctival autograft: The gold‑standard. The pterygium is removed and a piece of the patient’s own conjunctiva (usually from the superior bulbar area) is transplanted to cover the defect, reducing recurrence to <5%.
• Amniotic membrane transplantation (AMT): Uses preserved human amniotic tissue as a graft; recurrence rates 10–15%.
• Adjunctive mitomycin‑C (MMC): A chemotherapeutic agent applied intra‑operatively or post‑operatively to inhibit fibroblast proliferation; effective but carries risk of scleral thinning if misused.
• Limbal stem‑cell autograft: In recurrent or large lesions, a graft containing limbal stem cells can restore normal epithelial turnover.

Post‑operative care

• Topical antibiotics for 1 week to prevent infection.
• Prescribed steroid drops tapering over 4–6 weeks to control inflammation.
• Continued use of UV‑blocking eyewear for at least 6 months, preferably lifelong.
• Follow‑up visits at 1 week, 1 month, and 3 months to monitor healing and check for recurrence.

Living with Eye Pterygium

Daily management tips

• Artificial tears: Use preservative‑free drops 4–6 times daily if you have dryness.
• Protective eyewear: Wear sunglasses whenever you are outdoors, even on cloudy days.
• Stay hydrated: Adequate fluid intake helps maintain a healthy tear film.
• Regular eye exams: Schedule an optometric check‑up at least once a year, or sooner if you notice vision changes.
• Avoid eye rubbing: Mechanical trauma can exacerbate growth.
• Manage allergies: Use antihistamine eye drops if you have seasonal allergic conjunctivitis.

Eye‑care routine example

1. Morning: Wash face, apply preservative‑free artificial tears.
2. Mid‑day: Wear wrap‑around UV sunglasses and a hat if outside.
3. Evening: Re‑apply lubricating drops, note any new redness or itching.
4. Weekly: Inspect the eye in a mirror for any change in size or color of the lesion.

Prevention

Because UV exposure is the main driver, preventive strategies focus on protection and ocular surface health.

• UV‑blocking sunglasses: Choose lenses that block 100% UVA and UVB (look for the label “UV400”).
• Wide‑brimmed hats: A brim of at least 3 inches reduces peripheral UV.
• Use of protective goggles: For high‑wind or dusty work (e.g., farming, welding).
• Limit exposure during peak UV hours: 10 am–4 pm.
• Regular ocular surface care: Lubricating drops and treating dry eye early.
• Smoking cessation: Tobacco smoke contributes to ocular surface inflammation.

Complications

If left untreated or if surgery fails, several complications may arise:

• Corneal astigmatism: The pterygium’s mechanical tension can flatten the cornea, causing blurred vision.
• Reduced visual acuity: Direct encroachment over the pupil blocks the visual axis.
• Recurrent inflammation: Persistent redness may lead to chronic conjunctivitis.
• Scar formation (dellen): Localized thinning of the cornea adjacent to a large pterygium.
• Recurrence after surgery: Up to 30% recurrence with simple excision; lower with grafting and adjuvant MMC.
• Rare malignant transformation: Extremely uncommon, but pterygium‑like growth can occasionally harbor dysplastic cells; biopsy is warranted for atypical lesions.

When to Seek Emergency Care

References

1. Mayo Clinic. “Pterygium.” 2023. https://www.mayoclinic.org
2. World Health Organization. “Ultraviolet radiation and the eye.” 2022. https://www.who.int
3. National Eye Institute (NEI). “Prevalence of Pterygium in the United States.” 2021.https://nei.nih.gov
4. Cleveland Clinic. “Pterygium Surgery: What to Expect.” 2024. https://my.clevelandclinic.org
5. American Academy of Ophthalmology. “Preferred Practice Pattern Guidelines for Pterygium.” 2022.
6. J. G. Kwon et al., “Long‑term outcomes of conjunctival autograft with mitomycin‑C for primary pterygium,” *Ophthalmology*, vol. 129, no. 3, 2022.

```